[Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity

Rhea-AI Filing Summary

Supernus Pharmaceuticals (SUPN) senior officer reports equity award activity in a Form 4 filing. The Sr. VP of IP and Chief Scientific Officer reported a transaction dated 11/13/2025 involving derivative securities. The filing shows an acquisition of 1,500 Performance Share Units at an exercise price of $0, each linked to one share of common stock, leaving the officer with 1,500 derivative securities held directly. The non-derivative table indicates 13,718 shares of common stock beneficially owned directly following the reported transaction. An accompanying note explains that these Performance Share Units were originally awarded on February 22, 2022, with a portion vesting upon achievement of individual performance objectives set on May 3, 2022.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bhatt Padmanabh P.

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr. VP of IP, CSO

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								13,718	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Share Unit	$0	11/13/2025		A		1,500		(1)	(1)	Common Stock	1,500	$0	1,500	D

Explanation of Responses:

1. On February 22, 2022, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Supernus Pharmaceuticals (SUPN) report in this Form 4?

The Form 4 reports that the Sr. VP of IP and Chief Scientific Officer of Supernus Pharmaceuticals had a transaction dated 11/13/2025 involving the acquisition of derivative securities in the form of Performance Share Units.

How many Performance Share Units did the Supernus (SUPN) officer acquire?

The officer acquired 1,500 Performance Share Units, each tied to one share of Supernus Pharmaceuticals common stock, at a stated exercise price of $0.

How many Supernus (SUPN) shares does the reporting person own after this transaction?

Following the reported transaction, the filing shows the officer beneficially owning 13,718 shares of Supernus common stock directly, along with 1,500 derivative securities held directly.

What role does the reporting person hold at Supernus Pharmaceuticals (SUPN)?

The reporting person is identified as an officer of Supernus Pharmaceuticals, serving as Sr. VP of IP, CSO (Senior Vice President of Intellectual Property and Chief Scientific Officer).

When were the Performance Share Units originally granted to the Supernus (SUPN) officer?

The explanation notes that the Performance Share Units were awarded on February 22, 2022, with a portion vesting based on individual performance objectives.

What conditions were tied to the vesting of the Supernus (SUPN) Performance Share Units?

The filing explains that a portion of the Performance Share Units vested upon the achievement of individual performance objectives within a defined performance period, with those objectives established on May 3, 2022.